Evotec (NASDAQ: EVO) recently received a number of ratings updates from brokerages and research firms:
- 7/21/2026 – Evotec had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/16/2026 – Evotec was downgraded by Berenberg Bank from “buy” to “hold”.
- 7/15/2026 – Evotec had its price target lowered by HC Wainwright from $7.00 to $4.00. They now have a “buy” rating on the stock.
- 7/15/2026 – Evotec was downgraded by TD Cowen from “buy” to “hold”. They now have a $2.00 price target on the stock.
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Featured Stories
- Five stocks we like better than Evotec
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.
